Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
|
Title of Security |
CUSIP No. |
Acceptance |
Principal Amount |
Principal Amount |
Approximate |
Anticipated |
|
3.950% Notes due 2047 |
532457 |
1 |
$750,000,000 |
$313,871,000 |
41.85% |
$313,871,000 |
|
3.700% Notes due 2045 |
532457 |
2 |
$800,000,000 |
$387,533,000 |
48.44% |
$387,533,000 |
|
3.875% Notes due 2039 |
532457 |
3 |
$850,000,000 |
$489,255,000 |
57.56% |
$489,255,000 |
|
7.125% Notes due 2025 |
532457 |
4 |
$252,166,000 |
$22,474,000 |
8.91% |
$22,474,000 |
|
6.77% Notes due 2036 |
532457 |
5 |
$194,960,000 |
$20,515,000 |
10.52% |
$20,515,000 |
|
5.950% Notes due 2037 |
532457 |
6 |
$296,134,000 |
$12,022,000 |
4.06% |
$12,022,000 |
|
5.55% Notes due 2037 |
532457 |
7 |
$529,306,000 |
$53,154,000 |
10.04% |
$53,154,000 |
|
5.50% Notes due 2027 |
532457 |
8 |
$445,783,000 |
$68,278,000 |
15.32% |
$68,278,000 |
|
4.650% Notes due 2044 |
532457 |
9 |
$88,016,000 |
$45,000,000 |
51.13% |
$45,000,000 |
|
3.100% Notes due 2027 |
532457 |
10 |
$750,000,000 |
$348,550,000 |
46.47% |
$348,550,000 |
|
2.750% Notes due 2025 |
532457 |
11 |
$800,000,000 |
$453,083,000 |
56.64% |
$239,354,000 |
|
3.375% Notes due 2029 |
532457 |
12 |
$1,150,000,000 |
$379,995,000 |
33.04% |
$0 |
|
3.950% Notes due 2049 |
532457 |
13(1) |
$1,500,000,000 |
$325,162,000 |
21.68% |
$0 |
|
4.150% Notes due 2059 |
532457 |
14(2) |
$1,000,000,000 |
$309,404,000 |
30.94% |
$0 |
|
2.350% Notes due 2022 |
532457 |
15(3) |
$750,000,000 |
$250,848,000 |
33.45% |
$0 |
|
(1) The maximum principal amount of 3.950% Notes due 2049 that will be purchased by Lilly is $200,000,000. |
||||||
|
(2) The maximum principal amount of 4.150% Notes due 2059 that will be purchased by Lilly is $200,000,000. |
||||||
|
(3) The maximum principal amount of 2.350% Notes due 2022 that will be purchased by Lilly is $250,000,000. |
||||||
Subject to the conditions in the Offer to Purchase, Notes validly tendered and not validly withdrawn at or prior to the early tender date with Acceptance Priority Level 11 have been accepted for purchase using a proration factor of approximately 52.8%.
The settlement date for the notes accepted by Lilly in connection with the early tender date currently is expected to be on
Lilly expects to determine the pricing terms of the tender offer at
Holders of notes subject to the tender offer who validly tendered and did not validly withdraw their notes on or prior to the early tender date are eligible to receive the total consideration, which includes an early tender premium of
In accordance with the terms of the tender offer, the withdrawal date was
The tender offer is being conducted upon the terms and subject to the conditions set forth in the Offer to Purchase, dated
Lilly has retained
Requests for documents relating to the tender offer may be directed to
This press release is for informational purposes only and is not a tender offer to purchase or a solicitation of acceptance of a tender offer, which may be made only pursuant to the terms of the Offer to Purchase. In any jurisdiction where the laws require the tender offer to be made by a licensed broker or dealer, the tender offer will be deemed made on behalf of Lilly by the dealer managers, or one or more registered brokers or dealers under the laws of such jurisdiction. In addition, this press release is not an offer to sell or the solicitation of an offer to buy any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any such securities will be offered only by means of a prospectus, including a prospectus supplement relating to such securities, meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. F-LLY
This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "expect", "believe", "target" and similar expressions are intended to identify forward-looking statements, including but not limited to statements about the terms and conditions of, and the completion of, the tender offer. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of Lilly, that may cause its actual results to differ materially from those indicated in its forward-looking statements. For a further discussion of these risks and uncertainties, please see Lilly's latest Form 10-K and subsequent filings with the
|
Refer to: |
Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media) |
|
Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors) |
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-announces-the-early-tender-results-and-upsizing-of-its-pending-cash-tender-offer-to-up-to-2-000-006-000-aggregate-principal-amount-of-its-outstanding-debt-securities-300953901.html
SOURCE